37 results
Thumbnail

D1.264 - Assessment by general practitioners of a therapeutic patient education guide for allergic patients

Thumbnail

D1.262 - Clinical significance of a basophil activation test for Japanese beekeepers naturally sensitized to honey bee venom

Thumbnail

D1.265 - Component-Resolved Diagnosis and Clinical Profiles of Anisakis Allergy in Japan

Thumbnail

D1.266 - Investigation of anaphylaxis in mastocytosis mouse models

Thumbnail

D1.267 - Recurrence of perioperative anaphylaxis: analysis of a multicenter cohort

Thumbnail

D1.268 - The endothelial glycocalyx as a therapeutic target in anaphylaxis

Thumbnail

D1.269 - Deciphering cardiovascular profiles in sera and extracellular vesicles from anaphylactic patients. Impact in endothelial cells

Thumbnail

D1.270 - Anaphylaxis and Adrenaline: Knowledge gaps with critical consequences

Thumbnail

D1.271 - Bovine gelatine-induced anaphylaxis brought on by eating beef, sweets containing gelatin, and medications

Thumbnail

D1.272 - Efficacy and Safety of Omalizumab in Treating Severe Allergic Reactions with Urticaria as the Initial Symptom

Thumbnail

D1.273 - Anaphylactic Reaction Following Sulphur Hexafluoride Administration

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Thumbnail

D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center